KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
Before 2027 35%-1.0ptLeader of 3 outcomes
Market quality
42 / 100
Low quality24h Volume
$2.2
Liquidity
$34.5K
High liquiditySpread
8.0 pt
Wide spreadMarket data
Updated 11 minutes ago
Mar 24, 26, 2:00 PM UTCJan 1, 27, 4:59 AM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA moves BPC-157 to Category 1 by which date?
PolymarketHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiWill we get AGI before 2027?
Manifold MarketsFDA approves skin cancer vaccine by which date?
PolymarketMeasles cases in 2026?
KalshiRules
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
Settles via:Food and Drug Administration
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
Frequently asked questions
- What are the current odds for When will the FDA reclassify BPC-157 to Category 1??
- Kalshi prices Before 2027 at 35% as of September 9, 2026.
- When does When will the FDA reclassify BPC-157 to Category 1? resolve?
- When will the FDA reclassify BPC-157 to Category 1? is scheduled to resolve on January 1, 2027.
- How is When will the FDA reclassify BPC-157 to Category 1? settled?
- Kalshi settles this market as follows: If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.